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ABSTRACT
Increased circulating levels of apolipoprotein A-I (apoA-I), the major protein of 
high-density lipoprotein (HDL), by genetic manipulation or infusion, protects against 
melanoma growth and metastasis. Herein, we explored potential roles in melanoma 
tumorigenesis for host scavenger receptor class B, type 1 (SR-B1), and ATP-binding 
cassette transporters A1 (ABCA1) and G1 (ABCG1), all mediators of apoA-I and HDL 
sterol and lipid transport function. In a syngeneic murine melanoma tumor model, 
B16F10, mice with global deletion of SR-B1 expression exhibited increased plasma 
HDL cholesterol (HDLc) levels and decreased tumor volume, indicating host SR-B1 
does not directly contribute to HDL-associated anti-tumor activity. In mice with 
myeloid-specific loss of ABCA1 (Abca1-M/-M; A1-M/-M), tumor growth was inhibited by 
~4.8-fold relative to wild type (WT) animals. Abcg1-M/-M (G1-M/-M) animals were also 
protected by 2.5-fold relative to WT, with no further inhibition of tumor growth in 
Abca1/Abcg1 myeloid-specific double knockout animals (DKO). Analyses of tumor-
infiltrating immune cells revealed a correlation between tumor protection and 
decreased presence of the immune suppressive myeloid-derived suppressor cell 
(MDSC) subsets, Ly-6G+Ly-6CLo and Ly-6GnegLy-6CHi cells. The growth of the syngeneic 
MB49 murine bladder cancer cells was also inhibited in A1-M/-M mice. Collectively, 
our studies provide further evidence for an immune modulatory role for cholesterol 
homeostasis pathways in cancer.
INTRODUCTION
Previously, we reported an anti-tumorigenic activity 
for apoA-I and HDL against melanoma [1]. Mice genetically 
manipulated to express human apoA-I (apoA-I Tg) were 
protected from tumor growth and metastases, whereas 
apoA-I-deficient (apoA-I KO) animals exhibited increased 
susceptibility to tumor proliferation [1]. Therapeutic 
delivery of human apoA-I into mice demonstrated anti-
tumor activity in both established syngeneic mouse and 
xenograft human melanoma tumors. Both innate and 
adaptive immune arms were required for complete apoA-I 
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anti-tumor activity, which was enabled in part through 
modulation of tumor infiltrating immune cells [1].
The athero-protective activities of HDL, namely 
lipid efflux and anti-inflammatory effects, are in major 
part thought to be mediated by the three known HDL 
or apoA-I receptors: ATP-binding cassette (ABC) 
transporters A1 (ABCA1) and G1 (ABCG1), and the 
scavenger receptor class B, type 1 (SR-B1) [2-4]. ABCA1 
effluxes excess cholesterol and phospholipid to lipid-
poor apoA-I, the predominant protein in HDL [5, 6], 
whereas ABCG1 mediates cholesterol and lipid transport 
to an already assembled HDL particle [7-9]. Efflux 
activity of ABCA1 initiates HDL assembly and defects 
in ABCA1-mediated cholesterol efflux lead to nearly 
non-detectable plasma HDL cholesterol (HDLc) levels 
in the mouse [10, 11] or Tangier disease in humans [12-
15]. ABCA1 and ABCG1 are known to regulate several 
biological functions of hematopoietic cells. For example, 
mice deficient in ABCA1 and ABCG1 display hyper-
proliferation of hematopoietic stem and progenitor cells 
(HSPCs), with specific expansion of the myeloid and 
granulocyte macrophage progenitors [2]. This expansion 
leads to increased mobilization and activation of 
myeloid cells, resulting in monocytosis and neutrophilia. 
Genetic knockdown of ABCA1 and ABCG1 also led 
to increased surface expression of Toll-like receptor 4 
(TLR4) and heightened inflammatory gene expression 
[2, 16]. These observed effects were correlated with 
cholesterol accumulation in the transporter-deficient cells. 
Significantly, transplantation of bone marrow cells with 
genetic knockout of Abca1 and Abcg1 into mouse models 
prone to developing atherosclerosis resulted in accelerated 
atherosclerosis, underscoring an athero-protective role for 
these transporters in myeloid cells [2-4]. ABCA1 has been 
shown to possess anti-inflammatory activity, presumably 
via its cholesterol effluxing capacity to apoA-I [17]. 
ABCG1 similarly has anti-inflammatory activity, and is 
even more potent than ABCA1 in modulating cholesterol 
levels in the plasma membrane [16]. SR-B1, encoded 
by Scarb1, is the primary receptor for selective uptake 
of cholesteryl ester from HDL particles, and has also 
been reported to have an anti-inflammatory function in 
macrophages by suppressing Toll-like receptor-4 (TLR4) 
and nuclear factor-κB (NF-κB) signaling pathways [18].
In cancer cells, pharmacological and genetic 
evidence suggest a tumor-promoting role for cholesterol 
[19], and a tumor-inhibitory role for cholesterol efflux 
pathways [20]. For example, in prostate cancer cells 
inhibition of ABCA1, which effluxes cholesterol, resulted 
in tumor progression [19]. Conversely, elimination of SR-
B1 in breast cancer cells, which overexpress this receptor, 
lead to inhibition in tumor growth, suggestive of a tumor 
permissive role for SR-B1 in cancer cells [21].
In contrast to their role in some cancer cells, 
cholesterol efflux transporters appear to promote a 
tumor-supportive function in immune cells. Tumor-
mediated immune suppression is orchestrated by a 
number of infiltrating immune cell types including tumor 
associated macrophages (TAMs) and myeloid derived 
suppressor cells (MDSCs). TAMs and MDSCs both help 
promote tumor angiogenesis and metastasis, as well as 
tumor immune evasion. MDSCs are functionally and 
morphologically heterogeneous immature cell populations 
that fail to differentiate into mature dendritic cells, 
granulocytes, or macrophages, and are reported to inhibit 
the function of T cells, natural killer (NK) cells and other 
immune cells by different mechanisms [22]. Two main 
subsets of MDSCs have been defined: polymorphonuclear 
– MDSCs (Ly-6G+ Ly-6CLo), which are granulocytic in 
appearance; and monocytic MDSCs (Ly-6GnegLy-6CHi) 
[23]. The anti-tumor function of apoA-I and HDL in the 
murine B16F10 melanoma tumor model is associated with 
changes in MDSCs and TAMs; however, the receptors 
involved and their impact on host immune surveillance 
remain unclear [1].
In a recent study, global and myeloid deficiency 
of ABCG1 was shown to be associated with reduced 
melanoma and bladder tumor growth in mice fed a 
“western”-type diet [24]. However, the functional role for 
alternative cholesterol efflux transporters, ABCA1 and 
SR-B1, in tumor growth and host immune surveillance, 
has not yet been reported. In this study we investigated 
the role of host cholesterol transporters ABCA1, ABCG1, 
and the HDL receptor SR-B1, on melanoma and bladder 
tumor growth. We report here that global deletion of SR-
B1 protects mice against B16F10 melanoma tumor growth 
and myeloid-specific deletion of either ABCA1 or ABCG1, 
or the combined myeloid deletion of both ABCA1 and 
ABCG1 in somatic cells, protects mice against B16F10 
melanoma tumor growth, with comparable results for 
ABCA1 in a syngeneic MB49 murine bladder cancer 
model. Our studies newly identify a potential melanoma 
tumor-permissive role for SR-B1 and myeloid ABCA1 in 
non-tumor somatic cells in tumor bearing hosts.
RESULTS
Global deletion of scavenger receptor class B, 
type 1 is protective against melanoma
To examine the impact of somatic cell SR-B1 on 
melanoma tumor growth, wild-type C57BL/6J mice 
(Scarb1+/+), or mice either heterozygous (Scarb1+/-) or 
homozygous (Scarb1-/-) for deletion of Scarb1, were 
inoculated subcutaneously with B16F10 melanoma cells 
(105 cells/flank) and tumor growth was monitored over 
time by caliper measurements. If SR-B1 plays a role 
in the anti-tumor effect observed with apoA-I or HDL 
(1), we would anticipate enhanced tumor growth in the 
absence of SR-B1. In contrast, however, tumor growth 
in Scarb1+/- mice was significantly (p<0.05) inhibited 
by approximately 3-fold relative to WT mice, with no 
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significant further reduction in growth of tumor observed 
in Scarb1-/- mice (Figure 1A). Consistent with previous 
observations [25], significant increases in plasma total 
cholesterol (analysis of variance (ANOVA) between 
Figure 1: Global deletion of scavenger receptor B1 (SR-B1) is protective against melanoma. C57BL/6 animals wild type 
(Scarb1+/+), hetero- (Scarb1+/-) or homozygously (Scarb1-/-) deleted at the locus for scavenger receptor type B, class 1 gene (Scarb1) were 
inoculated subcutaneously (105 cells/flank) with B16F10 melanoma cells on day 0. (A) Tumor development was monitored by caliper 
measurements and tumor volume was calculated as described in Materials and Methods. n = number of inoculation sites, 2 sites/animal. 
Results shown are the mean ± SEM of a single experiment and are representative of repeat experiments. (B) Tumor bearing animals were 
sacrificed 21-days post tumor inoculation and plasma lipid distribution was determined as described in Materials and Methods. The median 
for each group is indicated. p values between two groups were determined by Student’s t-test. Analysis of variance (ANOVA) across all 
three groups is shown above each graph.
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the groups p<0.01) were observed in mice with genetic 
deletion of Scarb1 relative to WT mice (Figure 1B; 38% 
increase, WT vs Scarb1+/-, and 89% increase, WT vs 
Scarb1-/-). Further, lipoprotein subfractionation revealed 
Figure 2: Mice with myeloid-specific deletion of ATP-binding cassette transporter ABCA1 are protected against 
melanoma- additive deletion in ABCG1 did not provide further protection. C57BL/6 mice with wild type (WT; LysM-Cre 
Abca1+/+Abcg1+/+), myeloid deletion of Abca1 (A1-M/-M), Abcg1 (G1-M/-M), or Abca1 and Abcg1 (DKO) were inoculated with B16F10 tumor 
cells (105 cells/flank) on day 0. (A) Tumor development was monitored by caliper measurements and tumor volume calculated as described 
in Materials and Methods. n = number of inoculation sites, 2 sites/animal. Results shown are the mean ± SEM. (B) Tumor bearing animals 
(B16F10 and MB49) were analyzed for plasma lipid distribution as described in Materials and Methods. The median for each group is 
indicated. p values between two groups were determined by Student’s t-test. Analysis of variance (ANOVA) across all four groups is shown 
above each graph.
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a 44% increase in HDLc in Scarb1+/- relative to WT, but 
no further increase in HDLc in Scarb1-/- (Figure 1B right 
panel). Interestingly, we observed a noticeable increase 
in LDLc in SR-B1 null mice (42±16, 73±13, and 128±7 
mg/dL LDLc in WT, Scarb1+/-, and Scarb1-/-, respectively, 
data not shown). This suggests that in our tumor-bearing 
animals the increased total plasma cholesterol in SR-B1 
null mice relative to Scarb1+/- (Figure 1B), may have 
primarily partitioned to LDL instead of HDL particles. 
The observation in the present study that changes in HDLc 
are inversely correlated with tumor volume is consistent 
with our previous finding that higher HDL levels are 
associated with enhanced protection against melanoma 
[1]. Collectively, these results suggest that the anti-tumor 
activity of elevated HDL levels are independent of host 
SR-B1 and that loss of this receptor in host somatic 
cells hinders syngeneic transplanted melanoma tumor 
development.
Mice with myeloid-specific deletion of ABCA1 
are protected against melanoma and bladder 
cancer while additive deletion of ABCG1 does 
not provide further tumor inhibition
We previously reported that myeloid cells constitute 
a major immune cell infiltrate in B16F10 melanoma and 
that TAMs from apoA-I transgenic mice, which were 
protected from tumor development, had an M1- pro-
inflammatory-like phenotype relative to TAMs from 
apoA-I knock-out mice [1]. Since SR-B1 does not appear 
to be involved in mediating this protective effect (Figure 
1A), we hypothesized that myeloid cells deficient in either 
ABCA1, ABCG1 or both, which in multiple studies have 
previously been noted to have an inflammatory gene 
signature [2, 16, 26-28], might be protective in a B16F10 
melanoma tumor model. To examine this possibility we 
used mice with myeloid-specific deletion of Abca1 (A1-
M/-M [28]), Abcg1 (G1-M/-M), or both Abca1 and Abcg1 
(double knock-out (DKO) [2]). These animals express the 
Cre recombinase (LysM-Cre) in myeloid cells only, thus 
deleting loxP-floxed Abca1 and Abcg1 in a tissue-specific 
manner. In this study, the WT control mice also express 
the Cre recombinase in myeloid cells (LysM-Cre) but 
lack loxP sites in Abca1 and Abcg1 genes. Animals were 
inoculated with B16F10 melanoma cells (105 tumor cells/
flank) and tumor development over time was quantified. 
Relative to WT mice, tumor growth was inhibited (on day 
19 post inoculation) by 4.8-, 2.5-, and 2.3-fold in A1-M/-M, 
G1-M/-M, and DKO, respectively (Figure 2A). Importantly, 
loss of myeloid Abca1 alone was sufficient to significantly 
inhibit tumor development (p=0.01), and additional 
deletion of Abcg1 in the same immune cells did not lead 
to enhanced suppression of tumor growth (Figure 2A). 
Furthermore, the anti-tumor effects observed were noted 
in relatively young (3-4 months) animals on regular chow 
diet and did not require either aged mice (6-7 months old) 
or a high fat “western”-type diet, as was recently reported 
as a requirement for tumor suppressive phenotype in 
Abcg1-/- mice [24]. ANOVA analysis of plasma lipid 
profiles across the groups showed significant differences 
in total cholesterol and HDLc (p<0.01). Moreover, while 
A1-M/-M or G1-M/-M mice showed no difference in total 
cholesterol level relative to WT, the myeloid specific DKO 
animals exhibited a modest (18-20%) but statistically 
significant decrease in plasma total cholesterol levels 
(p<0.01) relative to WT and each of the single receptor 
knock-out mice (Figure 2B, left panel). The reduction in 
circulating cholesterol in the DKO mice did not translate 
into a significant difference in HDLc between WT and 
DKO (Figure 2B, right panel). Hepatic (not myeloid) 
ABCA1 has been reported to be the major determinant 
of plasma HDLc levels [29]. Therefore, the modest but 
statistically significant increase in HDLc in the A1-M/-M 
group of mice was unexpected and may contribute to the 
tumor protection observed in this group, though a similar 
increase in HDLc was not observed in G1-M/-M or DKO 
(Figure 2B, right panel).
We next examined whether the tumor inhibition 
observed in animals with myeloid ablation of ABCA1 
was specific to B16F10 melanoma. Animals (6-7 months 
old) were inoculated subcutaneously (105 cells/flank) with 
an alternative syngeneic tumor model, MB49 bladder 
carcinoma cells, and tumor progression over time was 
subsequently followed by caliper measurements. After 
19-days there was a 5.7-fold inhibition in tumor volume 
in the A1-M/-M animals relative to WT controls (p=0.02), 
and a similar trend toward inhibition in DKO animals, 
although the numbers did not reach statistical significance 
(Figure 3). In contrast to B16F10 melanoma, we did not 
observe tumor protection in younger A1-M/-M mice (data 
not shown). These results suggest that the therapeutic 
targeting of myeloid ABCA1 may be effective against a 
wide spectrum of cancers.
Myeloid-specific deletion of ABCA1 and ABCG1 
inhibits tumor bed accumulation of MDSCs
Tumor proliferation is largely influenced by 
infiltrating immune cells, which are recruited and 
subverted by the tumor microenvironment to promote 
tumor growth and metastasis. Since myeloid cells 
constitute the majority of infiltrating immune cells in 
B16F10 melanoma [1], we sought to examine if myeloid-
specific transporter deletions influenced the composition 
of infiltrating leukocytes within the tumor bed. After 
inoculation of B16F10 cells, tumors were excised (day 19) 
and processed for FACs analyses, as described in Materials 
and Methods. Host immune cells were differentiated from 
tumor cells by surface staining for the hematopoietic 
leukocyte common antigen, CD45 [30]. In Figure 4A and 
4B, tumor volume and weight are shown for each group 
of mice. There was a 10-, 2.3-, and 4.7-fold inhibition in 
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median tumor volume on the day of sacrifice in A1-M/-M, 
G1-M/-M and myeloid-specific DKO mice, respectively 
relative to control WT mice, with only A1-M/-M and G1-M/-M, 
but not myeloid-specific DKO mice, showing significant 
differences (p=0.02, p=0.01, and p=0.08, respectively). 
The remaining panels in Figures 4 and 5 include contour 
diagrams to the left to illustrate gating used during flow 
cytometry, and the panels to the right represent scatter 
plots quantifying the number of tumor-infiltrating cells 
for the indicated surface antigens per gram tumor tissue in 
all four groups. The number of infiltrating CD45+ cells/g 
tumor was reduced by 2.8-, 1.6-, and 14-fold in A1-M/-M, 
G1-M/-M and DKO animals relative to WT (p=0.01, p<0.01, 
and p<0.01, respectively, Figure 4C). Myeloid cells 
(CD11b+) constituted nearly 50% or greater of these tumor 
infiltrating leukocytes (Figure 4D). Although there was a 
similar trend (decrease in receptor knock-out mice relative 
to WT) in levels of CD11b+F4/80+ macrophages (ANOVA 
p=0.15), the decrease was only statistically significant 
between WT and DKO (6-fold decrease, p<0.01, data not 
shown).
In mice, MDSCs are broadly characterized as 
CD11b+GR1+, where the myeloid differentiation antigen 
GR1 consists of two epitopes, Ly-6G and Ly-6C [23]. 
There were fewer MDSCs in tumors from all receptor 
knock out groups relative to WT controls (3.7-, 1.8-
, and 11-fold decrease in A1-M/-M, G1-M/-M, and DKO, 
respectively; p=0.01, p=0.08 and p<0.01, respectively, 
Figure 5A). Importantly, myeloid ablation of ABCA1 
resulted in an almost 11-fold decrease in granulocytic 
MDSCs, Ly-6G+Ly-6CLo (median= 0.64 and 0.06 X 106 
cells/gram tumor tissue in WT and A1-M/-M, respectively, 
p=0.04, Figure 5B, top plot). There was no statistically 
significant difference between G1-M/-M and WT (p=0.18, 
Figure 5B, top plot) but a significant 7-fold decrease 
in Ly-6G+Ly-6CLo cells in DKO (median= 0.64 and 
0.09 X 106 cells/gram tumor tissue in WT and DKO, 
respectively, p<0.05, Figure 5B, top plot). In contrast, 
Figure 3: Mice with myeloid-specific deletion of ABCA1, are protected against MB49 bladder cancer on normal chow 
diet. C57BL/6 mice with wild type (WT; LysM-Cre Abca1+/+Abcg1+/+), myeloid deletion of Abca1 (A1-M/-M) or Abca1 and Abcg1 (DKO) 
were inoculated with 105 MB49 cells/flank on day 0. Tumor development was monitored by caliper measurements and tumor volume 
calculated as described in Materials and Methods. n = number of inoculation sites, 2 sites/animal. Results shown are the mean tumor 
volume ± SEM. p values between two groups were determined by Student’s t-test.
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myeloid ablation of ABCG1 resulted in a statistically 
significant decrease (2.7-fold) in numbers of monocytic 
MDSCs, Ly-6GnegLy-6CHi (median=0.9 and 0.33 X 106 
cells/gram tumor tissue in WT and G1-M/-M, respectively, 
Figure 4: Myeloid-specific deletion of ABCA1 and ABCG1 transporters inhibits accumulation of leukocytes in tumor 
bed. C57BL/6 mice with wild type (WT; LysM-Cre Abca1+/+Abcg1+/+), myeloid deletion of Abca1 (A1-M/-M), Abcg1 (G1-M-M) or Abca1 and 
Abcg1 (DKO) were inoculated with B16F10 tumor cells (105 cells/flank) and sacrificed 19-days later. (A) Individual tumor volumes (2 
per animal) as determined by caliper measurement (see Materials and Methods) on day of sacrifice, day 19. (B) Pooled tumor weight per 
animal which were processed for FACs analyses. (C) Number of tumor infiltrating leukocytes (CD45+) per gram tumor tissue. Cells were 
gated on live. Resected tumors (two per animal) from individual mice (n=7, WT; n= 4, A1-M/-M and DKO, and n=5, G1-M/-M) were digested 
to obtain single cells for surface antigen staining and analysis by flow cytometry, as described in Materials and Methods. (D) Number of 
tumor infiltrating CD11b+ cells per gram tumor tissue. Cells were gated on live and CD45+. Representative FACs images to the left are 
WT Control and are gated on live (C), and live/CD45+ (D). p values between two groups were determined by Student’s t-test. Analysis of 
variance (ANOVA) across all four groups is shown above each graph.
Oncotarget71972www.impactjournals.com/oncotarget
p<0.01, Figure 5B, lower plot). There was even further 
decrease (15-fold) in the monocytic MDSC subset in 
DKO (median=0.9 and 0.06 X 106 cells/gram tumor 
tissue in WT and DKO, respectively, p<0.01, Figure 
Figure 5: Myeloid-specific deletion of ABCA1 and ABCG1 transporters inhibits accumulation of myeloid derived 
suppressor cells (MDSCs) in tumor bed. C57BL/6 mice with wild type (WT; LysM-Cre Abca1+/+Abcg1+/+), myeloid deletion of 
Abca1 (A1-M/-M), Abcg1 (G1-M-M) or Abca1 and Abcg1 (DKO) were inoculated with B16F10 tumor cells (105 cells/flank) and sacrificed 
19-days later. Resected tumors (two per animal) from individual mice (n=7, WT; n= 4, A1-M/-M and DKO, and n=5, G1-M/-M) were digested 
to obtain single cells for surface antigen staining and analysis by flow cytometry, as described in Materials and Methods. (A) Number of 
CD11b+GR1+ (MDSCs) per gram tumor tissue. (B) Number of Ly-6G+Ly-6CLo (granulocytic MDSCs) and Ly-6GnegLy-6CHi (monocytic 
MDSCs) per gram tumor. Representative FACs images to the left are WT Control and are gated on live/CD45+ (A), and on live/ CD45+/
CD11b+ (B). p values between two groups were determined by Student’s t-test. Analysis of variance (ANOVA) across all four groups is 
shown above each graph.
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Figure 6: Animals with myeloid-specific deletion of both ABCA1 and ABCG1 transporters (DKO) exhibit higher 
frequencies of splenic CD11b+, CD11b+GR1+, monocytic and granulocytic MDSCs. C57BL/6 mice with wild type (WT; 
LysM-Cre Abca1+/+Abcg1+/+), myeloid deletion of Abca1 (A1-M/-M), Abcg1 (G1-M/-M), and myeloid deletion of Abca1 and Abcg1 (DKO) were 
inoculated with B16F10 tumor cells (105 cells/flank) and sacrificed 19-days later. Individual spleens were processed for FACs analysis 
as described in Materials and Methods. Cells were gated on live for analysis. (A) Frequency of splenic CD11b+ cells. (B) Frequency of 
CD11b+GR1+. (C) Frequency of Ly-6GnegLy-6CHi. (D) Frequency of Ly-6G+Ly-6CLo. p values between two groups were determined by 
Student’s t-test. Analysis of variance (ANOVA) across all four groups is shown above each graph.
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5B, lower plot). There was no statistically significant 
difference in monocytic MDSCs between A1-M/-M and 
WT (p=0.06, Figure 5B, lower plot). These results 
suggest that myeloid ABCA1 may be important in the 
accumulation of granulocytic MDSCs (Ly-6G+Ly-6CLo) 
whereas myeloid ABCG1 may govern the frequency 
of monocytic MDSCs (Ly-6GnegLy-6CHi) in the tumor 
microenvironment. The lower numbers of MDSCs in 
animals with myeloid ablation of ABCA1 and ABCG1 
was specific to the tumor compartment as these cells 
were not decreased in the spleen of receptor knock-out 
mice relative to WT animals (Figure 6B, 6C, and 6D). 
In contrast to the tumor (Figure 4D), the frequency of 
CD11b+ cells increased by 1.6-fold in spleens of DKO 
(Figure 6A, p<0.01). The frequency of Ly-6Gneg Ly-6CHi 
cells was increased modestly (~1.5-fold) in the spleen 
of both A1-M/-M and DKO animals relative to WT (Figure 
6C, p=0.01 and p<0.01, respectively) and that of Ly-
6G+ Ly-6CLo cells was increased only in DKO (2.8-fold 
relative to WT, Figure 6D, p<0.01).
Analysis of complete blood cell count (CBC) 
with differentials in naïve (non-tumor bearing) mice 
revealed no significant differences between WT, A1-M/-M 
and DKO except for a mild but statistically significant 
elevation of monocytes in DKO vs A1-M/-M (0.3 ± 0.04 
vs 0.09 ± 0.03 X103 cells/μl blood in DKO and A1-M/-M, 
respectively, p<0.01; data not shown). Tumor-bearing 
(B16F10 melanoma) mice similarly showed no major 
defects in CBC + differential, except for a statistically 
significant decrease in numbers of circulating 
monocytes and neutrophils in A1-M/-M animals relative to 
WT, G1-M/-M or DKO (Table 1). Further, a trend towards 
elevated neutrophil count in tumor bearing G1-M/-M 
and DKO mice relative to WT and A1-M/-M mice was 
observed (Table 1).
DISCUSSION
Recently, several reports have collectively provided 
evidence for an immune modulatory role for cholesterol 
homeostasis pathways in cancer. Notably, large-scale 
human epidemiological studies have noted an inverse 
association between circulating HDLc levels and cancer 
risk [31, 32]. Furthermore, reduced plasma level of 
Table 1: Mice with myeloid specific deletion of ATP-binding cassette transporter ABCA1 exhibit reduced circulating 
monocytes and neutrophils.
























(103) 3.93 ± 0.78 2.22 ± 0.31 3.35 ± 0.61 3.63 ± 0.49 0.063 0.575 0.798 0.106 0.023 0.757
Neut 
(103) 1.03 ± 0.23 0.49 ± 0.1 1.38 ± 0.43 1.47 ± 0.45 0.046 0.460 0.338 0.050 0.014 0.891
Lymph 
(103) 2.48 ± 0.54 1.57 ± 0.23 1.65 ± 0.21 1.88 ± 0.14 0.153 0.202 0.457 0.809 0.373 0.453
Mono 
(103) 0.32 ± 0.09 0.08 ± 0.01 0.25 ± 0.05 0.17 ± 0.03 0.026 0.581 0.285 0.005 0.018 0.281
Eos 
(103) 0.02 ± 0.00 0.02 ± 0.00 0.02 ± 0.00 0.04 ± 0.00 0.938 0.470 0.136 0.532 0.122 0.001
Baso 
(103) 0.06 ± 0.02 0.05 ± 0.03 0.02 ± 0.01 0.04 ± 0.01 0.877 0.100 0.457 0.339 0.708 0.217
RBC 
(106) 3.79 ± 0.53 3.96 ± 0.82 2.93 ± 0.55 5.41 ± 0.79 0.860 0.270 0.099 0.315 0.265 0.018
PLT
 (104) 53.53 ± 7.40 50.90 ± 11.33
45.17 ± 
8.76
69.45 ± 10.46 0.846 0.471 0.232 0.697 0.301 0.103
HGB (g/dL) 4.64 ± 0.91 5.97 ± 1.26 4.36 ± 0.99 7.92 ± 1.14 0.395 0.836 0.046 0.334 0.326 0.039
HCT 
(%)
19.46 ± 2.42 19.20 ± 3.89
16.37 ± 
2.86
26.10 ± 3.36 0.955 0.417 0.131 0.572 0.258 0.050
Results from complete blood counts and differentials from tumor-bearing (B16F10 melanoma) mice on chow diet recovered at time of 
sacrifice by cardiac puncture, as described in Materials and Methods. Number of mice in each group is indicated (n). Results shown are 
the mean ± SEM. p-values were determined by Student’s t –test for the indicated comparison.
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apoA-I, the predominant protein in HDL, was identified 
as a biomarker in patients with early-stage ovarian cancer 
[33-38]. Animal studies have similarly demonstrated that 
elements of cholesterol homeostasis pathways impact 
tumor growth and development. For example, apoA-I/
HDL, a lipoprotein involved in cholesterol transport in the 
circulation, was shown to have anti-tumor activity against 
both syngeneic and xenogeneic tumor models in mouse 
[1, 39]. The ATP binding cassette transporters ABCA1 and 
ABCG1 promote efflux of excess cholesterol and lipids 
from peripheral cells to circulating HDL for delivery to the 
liver and excretion into bile and feces in a physiological 
process known as reverse cholesterol transport [40, 41]. 
ABCG1 was recently shown to influence the anti-tumor 
function of immune cells. Both global and myeloid 
deletion of Abcg1 led to increased tumor immunity in 
young tumor bearing animals when fed a “western”-type 
diet, but not a normal chow diet [24]. Interestingly, in aged 
animals (6-7 months old), the protection associated with 
Abcg1 deficiency was observed in chow-fed animals [24].
In the present study, we extend these observations, 
and examine the potential role of two distinct apoA-I/
HDL receptors in tumor biology. Global knockout 
of Scarb1 (SR-B1) in 2-3 month old tumor bearing 
animals on chow diet led to inhibition of B16F10 tumor 
development compared to WT animals (Figure 1A) and 
increased levels of circulating HDLc (Figure 1B). Further, 
mice with myeloid-specific deletion of Abca1 (A1-M/-M) 
were protected against tumor development in relatively 
young (3-4 months old) animals on normal chow diet 
(Figure 2A). G1-M/-M mice were also protected under these 
experimental conditions, though not as robustly as A1-M/-M 
(Figure 2A). Importantly, A1-M/-M mice were also notable 
for being resistant to MB49 bladder cancer, suggesting 
that the protective mechanism triggered by loss of myeloid 
ABCA1 may be effective against a wide spectrum of 
tumors (Figure 3A).
We previously showed an innate and adaptive 
immune-modulatory role for apoA-I levels in 
melanoma tumor biology [1]. Our present study 
suggests that the tumor protective effect of increasing 
apoA-I/HDL levels likely did not function through 
SR-B1, the primary receptor for HDL particles and 
a key regulator of total cholesterol levels [42, 43]. 
Tumor growth was significantly inhibited in animals 
heterozygous or homozygous for deletion in SR-B1 
(Figure 1A). Of interest, a role for SR-B1 in adaptive 
immunity has previously been suggested since Scarb1-/- 
mice were shown to have increased expression of 
the proinflammatory cytokines TNFα, and IL-6 
and inducible nitric oxide synthetase in circulation, 
increased frequency of splenic macrophages and 
impaired lymphocyte homeostasis with activated T and 
B cells [44]. Additionally, a further link between HDL 
and macrophage immune function was suggested by 
the observation that SR-B1 can mediate bidirectional 
cholesterol transfer between macrophages and HDL [45, 
46]. Of particular note, SR-B1-null mice were reported 
to have hyperinflammatory macrophages independent of 
altered cellular or membrane cholesterol content [47]. 
Whether the observed tumor immunity in our present 
study is associated with these previously reported 
phenotypic changes in immune cells of Scarb1-null mice 
is unknown.
In prior studies, the anti-neoplastic activity of 
apoA-I and HDL [1], and the tumor protection observed 
with Abcg1 deficiency [24], were suggested to be mediated 
in part by the myeloid immune cell subset. In particular, 
macrophages were noted to switch to an M1-like tumor-
fighting phenotype. Thus, TAMs recovered from tumor-
bearing apoA-I transgenic mice had a pro-inflammatory 
M1-like gene signature and peritoneal macrophages from 
these animals displayed enhanced cytotoxicity towards 
tumor cells relative to macrophages recovered from tumor-
bearing apoA-I-null mice [1]. Myeloid-specific loss of 
ABCA1 and or ABCG1 expression has been shown to 
impart a pro-inflammatory phenotype to these immune 
cells [2, 16, 24, 48, 49]. In the present study, we therefore 
hypothesized that mice with myeloid-specific Abca1 
deletion may exhibit resistance to tumor development. 
Our observations with chow-fed, tumor bearing mice are 
supportive of this hypothesis, and consistent with our 
previous observation that pro-inflammatory TAMS inhibit 
B16F10 tumor development [1].
The recently observed [24] anti-tumor phenotype 
with Abcg1 deficiency was also noted to be accompanied 
by enhanced Abca1 expression in TAMs, though the 
potential role of ABCA1 was not examined. In the present 
study, we show that myeloid loss of Abca1 alone was 
sufficient to confer enhanced tumor immunity in both 
melanoma (Figure 2) and bladder cancer (Figure 3). 
We also saw no further inhibition in the rate of tumor 
development by the additional loss of Abcg1 in myeloid 
cells (Figure 2A; compare DKO to A1-M/-M). Moreover, 
unlike the situation reported with ABCG1-myeloid 
deficiency where the tumor protective effect was observed 
under conditions of hypercholesterolemia [24], this does 
not appear to be a prerequisite to elicit tumor protection 
with ABCA1-myeloid deficiency.
Here, we identified a tumor protective function 
against B16F10 melanoma and MB49 bladder cancer 
in mice with myeloid deficiency in ABCA1 (A1-M/-M) 
or ABCA1 and ABCG1 (DKO). It is possible that this 
protection may be related to the previously reported 
proinflammatory anti-tumor phenotype (M1) of TAMS in 
these animals, a hypothesis that deserves further study [1, 
24]. In the present studies, while we saw no statistically 
significant difference in the numbers of TAMs per gram 
tumor between different genotypes (data not shown), 
we did observe a lower frequency of MDSCs in general 
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(CD11b+GR1+), as well as monocytic (Ly-6GnegLy-6CHi) 
and granulocytic MDSCs (Ly-6G+Ly-6CLo) in these 
animals (Figure 5A and 5B, respectively). We acknowledge 
that the correlation between MDSC prevalence and tumor 
burden is merely associative at this point and further 
experiments are needed to prove a causal relationship. 
We speculate the decrease in myeloid infiltration may be 
related to the inflammatory microenvironment around the 
tumor [50] since prior studies have shown A1-M/-M or DKO 
macrophages exhibit increased apoptosis and decreased 
migration into inflammatory settings [51]. It is also notable 
that Hedrick and colleagues similarly recently observed 
a lower frequency of macrophage infiltration into MB49 
tumors in G1-M/-M mice, as well as enhanced macrophage 
apoptosis in “western”-type diet fed Abcg1-/- MB49 tumor 
bearing mice [24]. On a chow diet, ABCA1 and ABCG1 
protein expression was shown to be reduced by >95% in 
macrophages from DKO [2]. DKO monocytes are reported 
to show >80% reduction in ABCA1 and ABCG1, whereas 
in neutrophils there was a >50% reduction in ABCA1, but 
no significant reduction in ABCG1 mRNA [2]. This may 
explain the synergistic reduction in monocytic MDSCs 
(Ly-6GnegLy-6CHi) in tumors from DKO animals (Figure 
5B, lower plot) but not that of granulocytic MDSCs (Ly-
6G+Ly-6CLo) (Figure 5B, top plot). Additional factors 
may be influencing MDSC numbers in tumors from 
DKO animals. For example, it has been shown that Ldlr-
/- mice transplanted with DKO bone marrow displayed 
neutrophilia on chow diet and monocytosis in addition 
to enhanced neutrophilia on western-type diet [2]. In 
the present study however, tumor bearing myeloid DKO 
animals did not exhibit statistically significant increased 
circulating levels of monocytes or neutrophils (Table 1). 
This discrepancy may be due to differences in genetic 
background (Ldlr-/-), diet (Western vs chow), or tumor-
driven effects in our study versus the previously published 
report [2]. Interestingly, we observed a significant increase 
in splenic CD11b+, CD11b+GR1+, Ly-6GnegLy-6CHi and 
Ly-6G+Ly-6CLo cells in DKO (Figure 6), arguing against 
defective migration as the sole underlying cause for 
lower frequency of MDSCs in tumors from DKO mice. 
Increased apoptosis in receptor null myeloid cells [51, 
52] is another potential contributor to the lower observed 
MDSC levels in receptor null animals. In contrast, A1-
M/-M tumor bearing animals had significantly reduced 
levels of blood monocytes and neutrophils (Table 1), 
a trend that was not reflected in the spleen (Figure 6). 
It is thus plausible that in A1-M/-M animals MDSCs may 
not accumulate in the tumor bed in part because of lower 
levels of circulating monocytic immune cells.
Our present studies add to the growing support for 
the notion that loss of ABCA1 and ABCG1 in myeloid 
cells modulates tumorigenesis through impacting the 
immune system. They also have several limitations 
worth noting. The observation that animals with myeloid 
deficiency of ABCA1 (A1-M/-M) and or ABCG1 (G1-M/-M) 
transporters had smaller B16F10 tumors and reduced 
accumulation of tumor-infiltrating MDSCs is, at present, 
only associative. Further investigation into the role of 
MDSCs in mediating the observed influence of myeloid 
Abca1 gene in tumorigenesis are needed to prove a 
specific role of this cell type in the observed effects on 
tumor growth. While the underlying mechanism of action 
by these cholesterol transporter proteins remain to be fully 
understood, it is of interest to note that previous reports 
have shown that modulating cholesterol levels at the 
plasma membrane, either biochemically or through the 
deletion of cholesterol transporters, can impact immune 
cell function and phenotype through changes in cellular 
signaling [2, 16, 24, 27, 28]. Thus, loss of ABCA1/ABCG1 
in our experimental setting may have altered macrophage 
signaling, as previously shown in Abca1-/-, Abcg1-/- or 
DKO macrophages [16]. For example, heightened TLR 
signaling is associated with deletion of the cholesterol 
transporters [16], and TLR signaling has been shown to 
play a crucial role in initiation of innate immune responses 
against cancer and subsequent induction of adaptive 
immune responses [53]. The role of TLR signaling in 
the present studies remain to be explored. It is reported 
that TLR signaling in both tumor cells and host immune 
cells is complex, with both potential pro-tumorigenic 
advantages to tumor cells and anti-tumor immunogenic 
immune cell responses to endogenous tumor-generated 
TLR ligands [54-56]. In addition to changing the immune 
cell phenotype, altered signaling in receptor-null immune 
cells may also affect the migration of these cells and their 
ability to home in to the tumor. One can also speculate that 
reduced MDSC accumulation in tumors from receptor-
null animals may thus in part be explained by defective 
‘homing’, as well as enhanced apoptosis [24, 51]. In 
normal inflammatory settings, apoA-I/HDL suppresses 
inflammatory responses in macrophages [57-59]. In the 
tumor microenvironment, apoA-I/HDL appears to promote 
inflammation by inducing the accumulation of M1-like 
pro-inflammatory TAMs that have anti-tumor activity 
[1]. The molecular basis for this shift in TAM phenotype 
in tumor-bearing mice is under further investigation, but 
in essence it is similar to our present observations for 
the myeloid-deleted transporters and those reported by 
Hedrick and colleagues [24]. Thus, it appears that the loss 
of ABCA1/ABCG1 in myeloid cells “hard-wires” these 
immune cells to become pro-inflammatory.
In conclusion, our present study adds to an emerging 
theme that cholesterol metabolism and tumor immunity 
are closely linked. Multiple clinical studies have shown an 
inverse association between circulating HDLc or apoA-I 
levels and cancer risk [31-38]. Furthermore, studies with 
liver X receptor (LXR) antagonists resulting in immune 
cell cholesterol accumulation indicate increased dendritic 
cell infiltration into tumors with beneficial effects [60, 
61]. Most recently, apoA-I and myeloid ABCG1 have 
been shown to influence the anti-tumor function of 
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immune cells [1, 24]. In the present studies, inhibiting 
cholesterol efflux pathways globally with SR-B1, or more 
specifically in myeloid cells by alternative approaches, 
including targeted deletion of the transporters ABCA1 
alone, or ABCA1 in combination with ABCG1, resulted in 
significant reduction in tumor growth, and accompanying 
reduction in frequency of the immunosuppressive and 
tumor-promoting MDSCs. Further studies exploring both 
the mechanisms linking myeloid cholesterol transport 
and immune protection against cancer, and the anti-tumor 
potential of therapies that target immune cell cholesterol 
content, seem warranted.
MATERIALS AND METHODS
Materials and general procedures
All chemicals were from Sigma Chemical (St. 
Louis, MO) and all solvents were HPLC grade unless 
otherwise indicated. All mouse studies were performed 
under protocols approved by the Institutional Animal Care 
and Use Committee at the Cleveland Clinic.
Mice
Scavenger receptor class B, type 1 null (Scarb1-/-) 
mice used were back-crossed onto a C57BL/6J 
background for >>10 generations. LysM-Cre Abca1-M/-M 
Abcg1+/+ mice (referred to as A1-M/-M in this study) were 
provided by Dr. John Parks (Wake Forest University). Drs. 
Marit Westerterp and Alan Tall (Columbia University) 
provided LysM-Cre Abca1-M/-MAbcg1-M/-M mice (referred to 
as DKO in this study). LysM-Cre Abcg1-M/-M (referred to as 
G1-M/-M in this study) was bred out of DKO in our mouse 
facility by initially crossing the DKO with WT (LysM-Cre 
Abca1+/+Abcg1+/+) to obtain LysM-Cre Abca1+/+Abcg1-M/+ 
and then crossing these animals together to obtain 
homozygous floxed Abcg1 (LysM-Cre Abca1+/+Abcg1-
M/-M). Both myeloid-deleted ABC-transporter strains 
were backcrossed onto a C57BL/6J background for 
>>10 generations. C57BL/6J mice (referred to as wild 
type (WT)) were LysM-Cre Abca1+/+Abcg1+/+ and were 
provided by Dr. John Parks. All mice were bred at 
Cleveland Clinic’s Biological Research Unit (BRU).
Tumor cell lines
Mouse tumor cell line B16F10 melanoma was 
obtained from American Type Culture Collection 
(CRL-6475, ATTC, Bethesda, MD) and MB49 bladder 
cancer cells were a gift from Ernest Borden (Cleveland 
Clinic) and were established in 1979 following 
dimethylbenzanthracene treatment of C57BL/6J mice. 
Tumor cells were cultured in DMEM supplemented 
with 10% heat-inactivated fetal calf serum (FCS), 2 
mM L-glutamine and antibiotic/antimycotic (Invitrogen, 
Grand Island, NY) at 37° C and 5% CO2 in a humidified 
atmosphere. Cells used were mycoplasma-negative as 
determined by direct and indirect testing in the Cleveland 
Clinic Cell Culture Core.
In vivo tumor studies
Animals (B16F10 tumor experiments: 2-3 month 
old male & female (Scarb1); 3-4 month old female (WT, 
A1-M/-M, G1-M/-M and DKO) and MB49 bladder cancer 
experiments: 6-7 month old males (WT, A1-M/-M, and 
DKO)) were inoculated subcutaneously on both flanks 
with 105 tumor cells (in DMEM) per site. Tumor volume, 
based on caliper measurements, was calculated 3 times a 
week according to the ellipsoid volume formula: tumor 
volume = (the shortest diameter)2 x the largest diameter x 
0.525. Tumor volume is expressed as mean value where 
n= number of tumor inoculation sites (two per animal).
Flow cytometry
Splenocytes, were isolated by mechanical 
disruption. Individual spleens were cut into small pieces 
with sterile razor blade in cold RPMI medium and gently 
pressed through a 70 μm cell strainer using the rubber end 
of a syringe plunger. Cells were collected by centrifugation 
(300 x g, 7 min at 4°C) before being lysed for RBCs (LCK 
lysis buffer; A10492, Invitrogen). Individual tumors were 
chopped and digested using a tumor dissociation kit (130-
096-730, Miltenyi Biotec Inc, San Diego, CA, USA) and 
the mouse impTumor-02 program of the gentleMACS 
dissociator (Miltenyi Biotec Inc, San Diego, CA, USA) 
according to manufacturer’s protocol. Cells were lysed for 
RBC before surface staining. Fluorochrome-conjugated 
antibodies used were as follows: CD11b (CD11b-PE, 
clone M1/70, 12-0112, CD11b-FITC, clone M1/70, 11-
0112, eBioscience), GR1 (GR1-AF700, clone RB6-8C5, 
557979, BD Pharmingen), Ly-6C (Ly-6C-APC, clone AL-
21, 560595, BD Pharmingen), Ly-6G (Ly-6G-PE, clone 
1A8, 551461, BD Pharmingen), F4/80 (F4/80-FITC, clone 
BM8, 11-4801, eBioscience), CD45 (CD45 VioGreen; 
clone 30F11.1, 130-097-294, Miltenyi Biotec), CD3 
(CD3-AF700, clone 17A2, 561388, BD Pharmingen), 
CD4 (CD4-FITC, clone RM4-5, 11-0042, eBioscience), 
CD8a (CD8a-PerCP, clone 53-6.7, BD Pharmingen). 
Cells were gated on Live (Live/Dead Violet, L34955, 
Invitrogen), were acquired on a BD LSR II FACS machine 
and data analyzed using FlowJo software (Treestar Inc., 
Ashland, OR).
Lipid and complete blood count analyses
Blood was obtained by cardiac puncture at the 
time of sacrifice. Whole blood was run undiluted on 
an Advia 120 hematology system (Siemens Medical 
Solutions Malvern, PA, USA) for complete blood counts 
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and differentials. For total cholesterol, and HDLc levels, 
EDTA-plasma was prepared and analyzed on a Roche 
c311 clinical autoanalyzer in a CAP and CLIA accredited 
reference laboratory in the Center for Cardiovascular 
Diagnostics and Prevention at the Cleveland Clinic.
Statistical analysis
For tumor growth, error bars represent standard 
error of the mean (SEM). For CBC (Table 1) values are 
expressed as mean ± SEM. One way ANOVA (Analysis 
of variance) was used to analyze data across three or four 
genetic groups. Statistical differences between two groups 
were assessed by Student’s t –test whereby a probability 
value of p<0.05 was considered significant.
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